Exelixis (EXEL)

• Market cap: $10.9B
• 1 day: 3.32%
• 5 days: 7.04%
• 1 month: 7.1%
• 3 months: -2.22%
• 6 months: 9.24%
• Year to date: 19.15%
• 1 year: 46.52%
• 5 years: 50.11%
• 10 years: 550.16%
• Sector: Healthcare
• Industry: Biotechnology

About: Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Employees: 1,147

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

193% more first-time investments, than exits

New positions opened: 120 | Existing positions closed: 41

21% more capital invested

Capital invested by funds: $9.28B [Q1] → $11.2B (+$1.93B) [Q2]

13% more funds holding

Funds holding: 552 [Q1] → 624 (+72) [Q2]

3.48% more ownership

Funds ownership: 89.82% [Q1] → 93.3% (+3.48%) [Q2]

9% more repeat investments, than reductions

Existing positions increased: 232 | Existing positions reduced: 213

7% more call options, than puts

Call options by funds: $82.8M | Put options by funds: $77.6M

0% more funds holding in top 10

Funds holding in top 10: 10 [Q1] → 10 (+0) [Q2]

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $38
• Avg. target: $46
• High target: $60

13 analyst ratings

• positive: 8 62%
• neutral: 5 38%
• negative: 0 0%

Morgan Stanley Sean Laaman	$50	Overweight Maintained	17 Sep 2025
Goldman Sachs Paul Choi	$47	Buy Initiated	17 Sep 2025
Barclays Etzer Darout	$40	Equal-Weight Initiated	17 Sep 2025
HC Wainwright & Co. Robert Burns	$46	Buy Maintained	12 Aug 2025
UBS Ashwani Verma	$38	Neutral Maintained	30 Jul 2025